In human demyelinating diseases such as multiple sclerosis (MS), an imbalance between
demyelination and remyelination can trigger progressive degenerative processes. The …

Background Multiple sclerosis (MS) is an immune‐mediated disease of the central nervous
system affecting an estimated 1.3 million people worldwide. It is characterised by a variety of …

Multiple sclerosis (MS) treatment has received much attention, yet there is still no certain
cure. We herein investigate the therapeutic effect of olean-12-en-28-ol, 3β-pentacosanoate …

The blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) represent
two complex structures protecting the central nervous system (CNS) against potentially …

Blood–brain barrier (BBB) interface with multicellular structure controls strictly the entry of
varied circulating macromolecules from the blood-facing surface into the brain parenchyma …

The recent (re) discovery of the meningeal lymphatic system has opened new theories as to
how immune cells traffic and interact with the central nervous system (CNS). While evidence …

Background: Multiple sclerosis (MS) is characterized by a combination of inflammatory and
demyelination processes in the spinal cord and brain. Conventional drugs generally target …

The gut-associated lymphoid tissue is a primary activation site for immune responses to
infection and immunomodulation. Experimental evidence using animal disease models …

Multiple Sclerosis (MS) is a demyelinating disease of the human central nervous system
having an unconfirmed pathoetiology. Although animal models are used to mimic the …

The central nervous system (CNS) has been viewed as an immunologically privileged site,
but emerging works are uncovering a large array of neuroimmune interactions primarily …